CFTR Biomarker Studie Bei Patient*Innen Mit Mukoviszidose Und CFTR-Modulatortherapie
Status: Recruiting
Location: See all (4) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
This observational study evaluates the effect of therapy with cystic fibrosis transmembrane regulator (CFTR) modulators on CFTR function measured by the CFTR biomarker intestinal current measurement (ICM), nasal potential difference (NPD) and sweat chloride in a post-approval setting in patients with cystic fibrosis (CF).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 6 months
Healthy Volunteers: f
View:
• Decision for cystic fibrosis (CF) transmembrane regulator (CFTR)-modulator therapy by the patient and the caring CF physician
• Signed informed consent form (ICF) and, where appropriate, signed assent form.
Locations
Other Locations
Germany
Charité - Universitätsmedizin Berlin
RECRUITING
Berlin
Justus-Liebig-University Giessen
RECRUITING
Giessen
Hannover Medical School
RECRUITING
Hanover
University of Heidelberg
RECRUITING
Heidelberg
Contact Information
Primary
Simon Y Graeber, MD
simon.graeber@charite.de
+4930 450 566 587
Time Frame
Start Date: 2018-07-01
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 200
Related Therapeutic Areas
Sponsors
Collaborators: University of Giessen, Heidelberg University, Hannover Medical School
Leads: Charite University, Berlin, Germany